Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 13/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.50 |
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | GAA | P10253 | 9/20 | 0.50 |
| ▸ | NPC1 | O15118 | 8/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | USP2 | O75604 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3669063 | 0.83 | MEN1 (0.50) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL2835237 | 0.81 | LMNA (0.46) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL3668759 | 0.80 | PIK3CA (0.53) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL16437817 | 0.80 | LMNA (0.65) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL3512954 | 0.76 | LMNA (0.47) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL3510926 | 0.75 | LMNA (0.53) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL3513224 | 0.74 | PIK3CG (0.70) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL3511268 | 0.73 | PIK3CA (0.58) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL16500126 | 0.73 | MEN1 (0.65) | LMNAHTTMEN1KMT2AMAPT | |
| SCHEMBL3511497 | 0.73 | MEN1 (0.64) | LMNAHTTMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940771-B2 | Organic compounds | NOVARTIS AG (CH) | 2015-01-27 | — | — | US | disclosed |
| EP-2240475-B1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| EP-2238134-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080705-A2 | BIS-THIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163469-A1 | Organic Compounds | PIK3C3, PIK3CA, PIK3CD | LMNA 3168/4885HTT 3597/4885MEN1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.